Gilead Sciences, Inc. (NASDAQ:GILD) will release earnings results for the second quarter, after the closing bell on Thursday, ...

Now, let’s get to the juicy part. In a dataset that goes back to January 2019, the 4-6-U sequence has flashed 13 times on a ...

The stock's fall snapped a two-day winning streak.

This was the stock's second consecutive day of gains.

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting results this Thursday after market close. Here’s ...

Analysts expect Gilead Sciences to report an earnings per share (EPS) of $1.95. Investors in Gilead Sciences are eagerly ...

Gilead has returned the rights to a cancer candidate it licensed from Arcus Biosciences in a $725 million, multiprogram deal, ...

Gilead Sciences’ (NASDAQ: GILD) Q2 earnings are scheduled to be released on August 7, after market close. The pharma company ...

Biopharmaceuticals stock Gilead Sciences (NASDAQ: GILD) jumped 2.5% through 12:30 p.m. ET Friday after Needham & Co. upgraded ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the top cheap pharmaceutical stocks to buy now. Morgan Stanley analyst Terence ...

The largest group of Black physicians, thought leaders, and celebrities were in one room to have a needed discussion about HIV.

Now, it’s worth noting Stock Advisor’s total average return is 1,041% — a market-crushing outperformance compared to 183 % ...